Multinational Consensus

Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)

Sanjay Kalra, Stephen Atkin, Antonio Cervera, Ashok Kumar Das, Orgur Demir, Tevfik Demir, M. Fariduddin, Khoa Tuan Vo, Bon Jeong Ku, Ajay Kumar, Zafar A. Latif, Rachid Malek, Bien J. Matawaran, Roopa Mehta, Nam Quang Tran, Araceli Panelo, Sundeep Ruder, Joel Rodriquez Saldana, Khalid A. Shaikh, Amit Shakya & 2 others Dina Shrestha, A. G. Unnikrishnan

Research output: Contribution to journalArticle

Abstract

Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - 23 May 2018

Fingerprint

Insulin Aspart
Consensus
Insulin
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Fasting
Long-Acting Insulin
Short-Acting Insulin
Insulins
Glucose
Glycosylated Hemoglobin A
Hypoglycemia
Hypoglycemic Agents
insulin degludec
Therapeutics
Injections

Keywords

  • Co-formulation
  • Consensus
  • Hypoglycemia
  • IDegAsp

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Kalra, S., Atkin, S., Cervera, A., Das, A. K., Demir, O., Demir, T., ... Unnikrishnan, A. G. (Accepted/In press). Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp). Advances in Therapy, 1-9. https://doi.org/10.1007/s12325-018-0712-2

Multinational Consensus : Insulin Initiation with Insulin Degludec/Aspart (IDegAsp). / Kalra, Sanjay; Atkin, Stephen; Cervera, Antonio; Das, Ashok Kumar; Demir, Orgur; Demir, Tevfik; Fariduddin, M.; Vo, Khoa Tuan; Ku, Bon Jeong; Kumar, Ajay; Latif, Zafar A.; Malek, Rachid; Matawaran, Bien J.; Mehta, Roopa; Tran, Nam Quang; Panelo, Araceli; Ruder, Sundeep; Saldana, Joel Rodriquez; Shaikh, Khalid A.; Shakya, Amit; Shrestha, Dina; Unnikrishnan, A. G.

In: Advances in Therapy, 23.05.2018, p. 1-9.

Research output: Contribution to journalArticle

Kalra, S, Atkin, S, Cervera, A, Das, AK, Demir, O, Demir, T, Fariduddin, M, Vo, KT, Ku, BJ, Kumar, A, Latif, ZA, Malek, R, Matawaran, BJ, Mehta, R, Tran, NQ, Panelo, A, Ruder, S, Saldana, JR, Shaikh, KA, Shakya, A, Shrestha, D & Unnikrishnan, AG 2018, 'Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)', Advances in Therapy, pp. 1-9. https://doi.org/10.1007/s12325-018-0712-2
Kalra, Sanjay ; Atkin, Stephen ; Cervera, Antonio ; Das, Ashok Kumar ; Demir, Orgur ; Demir, Tevfik ; Fariduddin, M. ; Vo, Khoa Tuan ; Ku, Bon Jeong ; Kumar, Ajay ; Latif, Zafar A. ; Malek, Rachid ; Matawaran, Bien J. ; Mehta, Roopa ; Tran, Nam Quang ; Panelo, Araceli ; Ruder, Sundeep ; Saldana, Joel Rodriquez ; Shaikh, Khalid A. ; Shakya, Amit ; Shrestha, Dina ; Unnikrishnan, A. G. / Multinational Consensus : Insulin Initiation with Insulin Degludec/Aspart (IDegAsp). In: Advances in Therapy. 2018 ; pp. 1-9.
@article{0b7b1639af054e4997f370033afc891f,
title = "Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)",
abstract = "Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.",
keywords = "Co-formulation, Consensus, Hypoglycemia, IDegAsp",
author = "Sanjay Kalra and Stephen Atkin and Antonio Cervera and Das, {Ashok Kumar} and Orgur Demir and Tevfik Demir and M. Fariduddin and Vo, {Khoa Tuan} and Ku, {Bon Jeong} and Ajay Kumar and Latif, {Zafar A.} and Rachid Malek and Matawaran, {Bien J.} and Roopa Mehta and Tran, {Nam Quang} and Araceli Panelo and Sundeep Ruder and Saldana, {Joel Rodriquez} and Shaikh, {Khalid A.} and Amit Shakya and Dina Shrestha and Unnikrishnan, {A. G.}",
year = "2018",
month = "5",
day = "23",
doi = "10.1007/s12325-018-0712-2",
language = "English",
pages = "1--9",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",

}

TY - JOUR

T1 - Multinational Consensus

T2 - Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)

AU - Kalra, Sanjay

AU - Atkin, Stephen

AU - Cervera, Antonio

AU - Das, Ashok Kumar

AU - Demir, Orgur

AU - Demir, Tevfik

AU - Fariduddin, M.

AU - Vo, Khoa Tuan

AU - Ku, Bon Jeong

AU - Kumar, Ajay

AU - Latif, Zafar A.

AU - Malek, Rachid

AU - Matawaran, Bien J.

AU - Mehta, Roopa

AU - Tran, Nam Quang

AU - Panelo, Araceli

AU - Ruder, Sundeep

AU - Saldana, Joel Rodriquez

AU - Shaikh, Khalid A.

AU - Shakya, Amit

AU - Shrestha, Dina

AU - Unnikrishnan, A. G.

PY - 2018/5/23

Y1 - 2018/5/23

N2 - Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.

AB - Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.

KW - Co-formulation

KW - Consensus

KW - Hypoglycemia

KW - IDegAsp

UR - http://www.scopus.com/inward/record.url?scp=85047258390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047258390&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0712-2

DO - 10.1007/s12325-018-0712-2

M3 - Article

SP - 1

EP - 9

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -